Oncolytics Biotech Inc., of Calgary, Alberta, said it completed patient enrollment in its U.S. Phase II trial testing intravenous administration of oncolytic virus Reolysin in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST